RSS feed

Publications by Steinar Aamdal

117 publications found

Original articles

Aamdal E, Skovlund E, Jacobsen KD, Straume O, Kersten C, Herlofsen O, Karlsen J, Hussain I, Amundsen A, Dalhaug A, Nyakas M, Hagene KT, Holmsen K, Aamdal S, Kaasa S, Guren TK, Kyte JA (2022)
Health-related quality of life in patients with advanced melanoma treated with ipilimumab: prognostic implications and changes during treatment
ESMO Open, 7 (5), 100588
DOI 10.1016/j.esmoop.2022.100588, PubMed 36116420

Lee CJ, Modave E, Boeckx B, Kasper B, Aamdal S, Leahy MG, Rutkowski P, Bauer S, Debiec-Rychter M, Sciot R, Lambrechts D, Wozniak A, Schöffski P (2022)
Correlation of Immunological and Molecular Profiles with Response to Crizotinib in Alveolar Soft Part Sarcoma: An Exploratory Study Related to the EORTC 90101 "CREATE" Trial
Int J Mol Sci, 23 (10)
DOI 10.3390/ijms23105689, PubMed 35628499

Ellingsen EB, Aamdal E, Guren T, Lilleby W, Brunsvig PF, Mangsbo SM, Aamdal S, Hovig E, Mensali N, Gaudernack G, Inderberg EM (2022)
Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials
J Immunother Cancer, 10 (5)
DOI 10.1136/jitc-2021-004345, PubMed 35613827

Tryggestad AMA, Axcrona K, Axcrona U, Bigalke I, Brennhovd B, Inderberg EM, Hønnåshagen TK, Skoge LJ, Solum G, Saebøe-Larssen S, Josefsen D, Olaussen RW, Aamdal S, Skotheim RI, Myklebust TÅ, Schendel DJ, Lilleby W, Dueland S, Kvalheim G (2021)
Long-term first-in-man Phase I/II study of an adjuvant dendritic cell vaccine in patients with high-risk prostate cancer after radical prostatectomy
Prostate, 82 (2), 245-253
DOI 10.1002/pros.24267, PubMed 34762317

Aamdal E, Jacobsen KD, Straume O, Kersten C, Herlofsen O, Karlsen J, Hussain I, Amundsen A, Dalhaug A, Nyakas M, Schuster C, Hagene KT, Holmsen K, Russnes HG, Skovlund E, Kaasa S, Aamdal S, Kyte JA, Guren TK (2021)
Ipilimumab in a real-world population: A prospective Phase IV trial with long-term follow-up
Int J Cancer, 150 (1), 100-111
DOI 10.1002/ijc.33768, PubMed 34449877

Aamdal E, Inderberg EM, Ellingsen EB, Rasch W, Brunsvig PF, Aamdal S, Heintz KM, Vodák D, Nakken S, Hovig E, Nyakas M, Guren TK, Gaudernack G (2021)
Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial
Front Immunol, 12, 663865
DOI 10.3389/fimmu.2021.663865, PubMed 34046035

Nyakas M, Aamdal E, Jacobsen KD, Guren TK, Aamdal S, Hagene KT, Brunsvig P, Yndestad A, Halvorsen B, Tasken KA, Aukrust P, Maelandsmo GM, Ueland T (2019)
Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma
Clin Exp Immunol, 197 (1), 74-82
DOI 10.1111/cei.13283, PubMed 30821848

Schöffski P, Wozniak A, Leahy MG, Aamdal S, Rutkowski P, Bauer S, Richter S, Grünwald V, Debiec-Rychter M, Sciot R, Geoerger B, Marréaud S, Collette S, Nzokirantevye A, Strauss SJ (2018)
The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 'CREATE'
Eur J Cancer, 94, 156-167
DOI 10.1016/j.ejca.2018.02.011, PubMed 29567632

Schöffski P, Wozniak A, Kasper B, Aamdal S, Leahy MG, Rutkowski P, Bauer S, Gelderblom H, Italiano A, Lindner LH, Hennig I, Strauss S, Zakotnik B, Anthoney A, Albiges L, Blay JY, Reichardt P, Sufliarsky J, van der Graaf WTA, Debiec-Rychter M, Sciot R, Van Cann T, Marréaud S, Raveloarivahy T, Collette S et al. (2018)
Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'
Ann Oncol, 29 (3), 758-765
DOI 10.1093/annonc/mdx774, PubMed 29216400

Kyte JA, Gaudernack G, Faane A, Lislerud K, Inderberg EM, Brunsvig P, Aamdal S, Kvalheim G, Wälchli S, Pule M (2016)
T-helper cell receptors from long-term survivors after telomerase cancer vaccination for use in adoptive cell therapy
Oncoimmunology, 5 (12), e1249090
DOI 10.1080/2162402X.2016.1249090, PubMed 28123886

Kyte JA, Aamdal S, Dueland S, Sæbøe-Larsen S, Inderberg EM, Madsbu UE, Skovlund E, Gaudernack G, Kvalheim G (2016)
Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells
Oncoimmunology, 5 (11), e1232237
DOI 10.1080/2162402X.2016.1232237, PubMed 27999747

Sioud M, Nyakas M, Sæbøe-Larssen S, Mobergslien A, Aamdal S, Kvalheim G (2016)
Diversification of Antitumour Immunity in a Patient with Metastatic Melanoma Treated with Ipilimumab and an IDO-Silenced Dendritic Cell Vaccine
Case Rep Med, 2016, 9639585
DOI 10.1155/2016/9639585, PubMed 27504122

Andersson Y, Engebraaten O, Juell S, Aamdal S, Brunsvig P, Fodstad Ø, Dueland S (2015)
Phase I trial of EpCAM-targeting immunotoxin MOC31PE, alone and in combination with cyclosporin
Br J Cancer, 113 (11), 1548-55
DOI 10.1038/bjc.2015.380, PubMed 26554649

Venugopal B, Awada A, Evans TR, Dueland S, Hendlisz A, Rasch W, Hernes K, Hagen S, Aamdal S (2015)
A first-in-human phase I and pharmacokinetic study of CP-4126 (CO-101), a nucleoside analogue, in patients with advanced solid tumours
Cancer Chemother Pharmacol, 76 (4), 785-92
DOI 10.1007/s00280-015-2846-0, PubMed 26289594

Prasmickaite L, Berge G, Bettum IJ, Aamdal S, Hansson J, Bastholt L, Øijordsbakken M, Boye K, Mælandsmo GM (2015)
Evaluation of serum osteopontin level and gene polymorphism as biomarkers: analyses from the Nordic Adjuvant Interferon alpha Melanoma trial
Cancer Immunol Immunother, 64 (6), 769-76
DOI 10.1007/s00262-015-1686-4, PubMed 25832001

Maio M, Grob JJ, Aamdal S, Bondarenko I, Robert C, Thomas L, Garbe C, Chiarion-Sileni V, Testori A, Chen TT, Tschaika M, Wolchok JD (2015)
Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial
J Clin Oncol, 33 (10), 1191-6
DOI 10.1200/JCO.2014.56.6018, PubMed 25713437

Vihinen P, Tervahartiala T, Sorsa T, Hansson J, Bastholt L, Aamdal S, Stierner U, Pyrhönen S, Syrjänen K, Lundin J, Hernberg M (2014)
Benefit of adjuvant interferon alfa-2b (IFN-α) therapy in melanoma patients with high serum MMP-8 levels
Cancer Immunol Immunother, 64 (2), 173-80
DOI 10.1007/s00262-014-1620-1, PubMed 25319807

Eggermont AM, Suciu S, Rutkowski P, Marsden J, Santinami M, Corrie P, Aamdal S, Ascierto PA, Patel PM, Kruit WH, Bastholt L, Borgognoni L, Bernengo MG, Davidson N, Polders L, Praet M, Spatz A (2013)
Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial
J Clin Oncol, 31 (30), 3831-7
DOI 10.1200/JCO.2012.47.9303, PubMed 24019551

del Campo AB, Kyte JA, Carretero J, Zinchencko S, Méndez R, González-Aseguinolaza G, Ruiz-Cabello F, Aamdal S, Gaudernack G, Garrido F, Aptsiauri N (2013)
Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma
Int J Cancer, 134 (1), 102-13
DOI 10.1002/ijc.28338, PubMed 23784959

Vik-Mo EO, Nyakas M, Mikkelsen BV, Moe MC, Due-Tønnesen P, Suso EM, Sæbøe-Larssen S, Sandberg C, Brinchmann JE, Helseth E, Rasmussen AM, Lote K, Aamdal S, Gaudernack G, Kvalheim G, Langmoen IA (2013)
Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma
Cancer Immunol Immunother, 62 (9), 1499-509
DOI 10.1007/s00262-013-1453-3, PubMed 23817721

Brandberg Y, Johansson H, Aamdal S, Bastholt L, Hernberg M, Stierner U, von der Maase H, Hansson J, Nordic Melanoma Cooperative Group (2013)
Role functioning before start of adjuvant treatment was an independent prognostic factor for survival and time to failure. A report from the Nordic adjuvant interferon trial for patients with high-risk melanoma
Acta Oncol, 52 (6), 1086-93
DOI 10.3109/0284186X.2013.789140, PubMed 23621752

Cohen RB, Aamdal S, Nyakas M, Cavallin M, Green D, Learoyd M, Smith I, Kurzrock R (2013)
A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies
Eur J Cancer, 49 (7), 1521-9
DOI 10.1016/j.ejca.2013.01.013, PubMed 23433846

Kaye S, Aamdal S, Jones R, Freyer G, Pujade-Lauraine E, de Vries EG, Barriuso J, Sandhu S, Tan DS, Hartog V, Kuenen B, Ruijter R, Kristensen GB, Nyakas M, Barrett S, Burke W, Pietersma D, Stuart M, Emeribe U, Boven E (2012)
Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours
Br J Cancer, 106 (11), 1728-34
DOI 10.1038/bjc.2012.158, PubMed 22531637

Brandberg Y, Aamdal S, Bastholt L, Hernberg M, Stierner U, von der Maase H, Hansson J (2011)
Health-related quality of life in patients with high-risk melanoma randomised in the Nordic phase 3 trial with adjuvant intermediate-dose interferon alfa-2b
Eur J Cancer, 48 (13), 2012-9
DOI 10.1016/j.ejca.2011.11.019, PubMed 22196968

Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, Carson WE, Chang AE, Characiejus D, Choudhury AR, Coukos G, de Gruijl T, Dillman RO, Dolstra H, Dranoff G, Durrant LG et al. (2011)
Defining the critical hurdles in cancer immunotherapy
J Transl Med, 9, 214
DOI 10.1186/1479-5876-9-214, PubMed 22168571

Hamid O, Schmidt H, Nissan A, Ridolfi L, Aamdal S, Hansson J, Guida M, Hyams DM, Gómez H, Bastholt L, Chasalow SD, Berman D (2011)
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
J Transl Med, 9, 204
DOI 10.1186/1479-5876-9-204, PubMed 22123319

Brunsvig PF, Kyte JA, Kersten C, Sundstrøm S, Møller M, Nyakas M, Hansen GL, Gaudernack G, Aamdal S (2011)
Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial
Clin Cancer Res, 17 (21), 6847-57
DOI 10.1158/1078-0432.CCR-11-1385, PubMed 21918169

Aamdal S (2011)
Current approaches to adjuvant therapy of melanoma
Eur J Cancer, 47 Suppl 3, S336-7
DOI 10.1016/S0959-8049(11)70193-9, PubMed 21944005

Kyte JA, Gaudernack G, Dueland S, Trachsel S, Julsrud L, Aamdal S (2011)
Telomerase peptide vaccination combined with temozolomide: a clinical trial in stage IV melanoma patients
Clin Cancer Res, 17 (13), 4568-80
DOI 10.1158/1078-0432.CCR-11-0184, PubMed 21586625

Suso EM, Dueland S, Rasmussen AM, Vetrhus T, Aamdal S, Kvalheim G, Gaudernack G (2011)
hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes
Cancer Immunol Immunother, 60 (6), 809-18
DOI 10.1007/s00262-011-0991-9, PubMed 21365467

Hansson J, Aamdal S, Bastholt L, Brandberg Y, Hernberg M, Nilsson B, Stierner U, von der Maase H, Nordic Melanoma Cooperative Group (2011)
Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial
Lancet Oncol, 12 (2), 144-52
DOI 10.1016/S1470-2045(10)70288-6, PubMed 21256809

Edvardsen H, Brunsvig PF, Solvang H, Tsalenko A, Andersen A, Syvanen AC, Yakhini Z, Børresen-Dale AL, Olsen H, Aamdal S, Kristensen VN (2010)
SNPs in genes coding for ROS metabolism and signalling in association with docetaxel clearance
Pharmacogenomics J, 10 (6), 513-23
DOI 10.1038/tpj.2010.6, PubMed 20157331

Bouwhuis MG, Suciu S, Collette S, Aamdal S, Kruit WH, Bastholt L, Stierner U, Salès F, Patel P, Punt CJ, Hernberg M, Spatz A, ten Hagen TL, Hansson J, Eggermont AM, EORTC Melanoma Group and the Nordic Melanoma Group (2009)
Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon
J Natl Cancer Inst, 101 (12), 869-77
DOI 10.1093/jnci/djp132, PubMed 19509353

Gunnes N, Seierstad TG, Aamdal S, Brunsvig PF, Jacobsen AB, Sundstrøm S, Aalen OO (2009)
Assessing quality of life in a randomized clinical trial: correcting for missing data
BMC Med Res Methodol, 9, 28
DOI 10.1186/1471-2288-9-28, PubMed 19405936

Dueland S, Aamdal S, Lind MJ, Thomas H, Sandvold ML, Gaullier JM, Rasch W (2009)
Intravenous administration of CP-4055 (ELACYT) in patients with solid tumours. A Phase I study
Acta Oncol, 48 (1), 137-45
DOI 10.1080/02841860802183620, PubMed 18607882

Faye RS, Paus E, Maelandsmo GM, Berner A, Høifødt HK, Fodstad Ø, Aamdal S (2008)
S100B in bone marrow aspirates in healthy individuals and malignant melanoma patients
Melanoma Res, 18 (2), 134-40
DOI 10.1097/CMR.0b013e3282f623d9, PubMed 18337650

Brunsvig PF, Flatmark K, Aamdal S, Høifødt H, Le H, Jakobsen E, Sandstad B, Fodstad O (2008)
Bone marrow micrometastases in advanced stage non-small cell lung carcinoma patients
Lung Cancer, 61 (2), 170-6
DOI 10.1016/j.lungcan.2007.12.018, PubMed 18261824

Helsing P, Nymoen DA, Ariansen S, Steine SJ, Maehle L, Aamdal S, Langmark F, Loeb M, Akslen LA, Molven A, Andresen PA (2008)
Population-based prevalence of CDKN2A and CDK4 mutations in patients with multiple primary melanomas
Genes Chromosomes Cancer, 47 (2), 175-84
DOI 10.1002/gcc.20518, PubMed 18023021

Brunsvig PF, Andersen A, Aamdal S, Kristensen V, Olsen H (2007)
Pharmacokinetic analysis of two different docetaxel dose levels in patients with non-small cell lung cancer treated with docetaxel as monotherapy or with concurrent radiotherapy
BMC Cancer, 7, 197
DOI 10.1186/1471-2407-7-197, PubMed 17956601

Hernberg M, Mattila PS, Rissanen M, Hansson J, Aamdal S, Bastholt L, von der Maase H, Schmidt H, Stierner U, Tarkkanen J (2007)
The prognostic role of blood lymphocyte subset distribution in patients with resected high-risk primary or regionally metastatic melanoma
J Immunother, 30 (7), 773-9
DOI 10.1097/CJI.0b013e31814e0898, PubMed 17893569

Kyte JA, Kvalheim G, Lislerud K, thor Straten P, Dueland S, Aamdal S, Gaudernack G (2006)
T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells
Cancer Immunol Immunother, 56 (5), 659-75
DOI 10.1007/s00262-006-0222-y, PubMed 16947019

Kyte JA, Mu L, Aamdal S, Kvalheim G, Dueland S, Hauser M, Gullestad HP, Ryder T, Lislerud K, Hammerstad H, Gaudernack G (2006)
Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA
Cancer Gene Ther, 13 (10), 905-18
DOI 10.1038/sj.cgt.7700961, PubMed 16710345

Brunsvig PF, Aamdal S, Gjertsen MK, Kvalheim G, Markowski-Grimsrud CJ, Sve I, Dyrhaug M, Trachsel S, Møller M, Eriksen JA, Gaudernack G (2006)
Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer
Cancer Immunol Immunother, 55 (12), 1553-64
DOI 10.1007/s00262-006-0145-7, PubMed 16491401

Andersen A, Warren DJ, Brunsvig PF, Aamdal S, Kristensen GB, Olsen H (2006)
High sensitivity assays for docetaxel and paclitaxel in plasma using solid-phase extraction and high-performance liquid chromatography with UV detection
BMC Clin Pharmacol, 6, 2
DOI 10.1186/1472-6904-6-2, PubMed 16412237

Mu LJ, Kyte JA, Kvalheim G, Aamdal S, Dueland S, Hauser M, Hammerstad H, Waehre H, Raabe N, Gaudernack G (2005)
Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients
Br J Cancer, 93 (7), 749-56
DOI 10.1038/sj.bjc.6602761, PubMed 16136047

Brunsvig PF, Hatlevoll R, Berg R, Lauvvang G, Owre K, Wang M, Aamdal S (2005)
Weekly docetaxel with concurrent radiotherapy in locally advanced non-small cell lung cancer: a phase I/II study with 5 years' follow-up
Lung Cancer, 50 (1), 97-105
DOI 10.1016/j.lungcan.2005.05.010, PubMed 16005105

Millward MJ, Joshua A, Kefford R, Aamdal S, Thomson D, Hersey P, Toner G, Lynch K (2005)
Multi-centre Phase II trial of the polyamine synthesis inhibitor SAM486A (CGP48664) in patients with metastatic melanoma
Invest New Drugs, 23 (3), 253-6
DOI 10.1007/s10637-005-6734-z, PubMed 15868382

Kyte JA, Kvalheim G, Aamdal S, Saebøe-Larssen S, Gaudernack G (2005)
Preclinical full-scale evaluation of dendritic cells transfected with autologous tumor-mRNA for melanoma vaccination
Cancer Gene Ther, 12 (6), 579-91
DOI 10.1038/sj.cgt.7700837, PubMed 15818380

Smyth JF, Aamdal S, Awada A, Dittrich C, Caponigro F, Schöffski P, Gore M, Lesimple T, Djurasinovic N, Baron B, Ravic M, Fumoleau P, Punt CJ, EORTC New Drug Development and Melanoma Groups (2005)
Phase II study of E7070 in patients with metastatic melanoma
Ann Oncol, 16 (1), 158-61
DOI 10.1093/annonc/mdi016, PubMed 15598954

Sundstrøm S, Bremnes RM, Kaasa S, Aasebø U, Aamdal S, Norwegian Lung Cancer Study Group (2004)
Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen)
Lung Cancer, 48 (2), 251-61
DOI 10.1016/j.lungcan.2004.10.016, PubMed 15829326

Faye RS, Aamdal S, Høifødt HK, Jacobsen E, Holstad L, Skovlund E, Fodstad Ø (2004)
Immunomagnetic detection and clinical significance of micrometastatic tumor cells in malignant melanoma patients
Clin Cancer Res, 10 (12 Pt 1), 4134-9
DOI 10.1158/1078-0432.CCR-03-0408, PubMed 15217950

Bos AM, Boom K, Vinks AA, Boezen HM, Wanders J, Dombernovsky P, Aamdal S, de Vries EG, Uges DR (2004)
Development of an optimal sampling strategy for clinical pharmacokinetic studies of the novel anthracycline disaccharide analogue MEN-10755
Cancer Chemother Pharmacol, 54 (1), 64-70
DOI 10.1007/s00280-004-0772-7, PubMed 15069581

Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, Weichenthal M, Neuber K, Bieber T, Gilde K, Guillem Porta V, Fra J, Bonneterre J, Saïag P, Kamanabrou D, Pehamberger H, Sufliarsky J, Gonzalez Larriba JL, Scherrer A, Menu Y (2004)
Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study
J Clin Oncol, 22 (6), 1118-25
DOI 10.1200/JCO.2004.04.165, PubMed 15020614

Sundstrøm S, Bremnes R, Aasebø U, Aamdal S, Hatlevoll R, Brunsvig P, Johannessen DC, Klepp O, Fayers PM, Kaasa S (2004)
Hypofractionated palliative radiotherapy (17 Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: a national phase III trial
J Clin Oncol, 22 (5), 801-10
DOI 10.1200/JCO.2004.06.123, PubMed 14990635

Cheng JD, Babb JS, Langer C, Aamdal S, Robert F, Engelhardt LR, Fernberg O, Schiller J, Forsberg G, Alpaugh RK, Weiner LM, Rogatko A (2004)
Individualized patient dosing in phase I clinical trials: the role of escalation with overdose control in PNU-214936
J Clin Oncol, 22 (4), 602-9
DOI 10.1200/JCO.2004.12.034, PubMed 14966084

Bremnes RM, Sundstrom S, Aasebø U, Kaasa S, Hatlevoll R, Aamdal S, Norweigian Lung Cancer Study Group (2003)
The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up
Lung Cancer, 39 (3), 303-13
DOI 10.1016/s0169-5002(02)00508-1, PubMed 12609569

Marchand M, Punt CJ, Aamdal S, Escudier B, Kruit WH, Keilholz U, Håkansson L, van Baren N, Humblet Y, Mulders P, Avril MF, Eggermont AM, Scheibenbogen C, Uiters J, Wanders J, Delire M, Boon T, Stoter G (2003)
Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report
Eur J Cancer, 39 (1), 70-7
DOI 10.1016/s0959-8049(02)00479-3, PubMed 12504661

Sundstrøm S, Bremnes RM, Kaasa S, Aasebø U, Hatlevoll R, Dahle R, Boye N, Wang M, Vigander T, Vilsvik J, Skovlund E, Hannisdal E, Aamdal S, Norwegian Lung Cancer Study Group (2002)
Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up
J Clin Oncol, 20 (24), 4665-72
DOI 10.1200/JCO.2002.12.111, PubMed 12488411

Bos AM, de Vries EG, Dombernovsky P, Aamdal S, Uges DR, Schrijvers D, Wanders J, Roelvink MW, Hanauske AR, Bortini S, Capriati A, Crea AE, Vermorken JB (2001)
Pharmacokinetics of MEN-10755, a novel anthracycline disaccharide analogue, in two phase I studies in adults with advanced solid tumours
Cancer Chemother Pharmacol, 48 (5), 361-9
DOI 10.1007/s002800100350, PubMed 11761453

Fodstad O, Faye R, Høifødt HK, Skovlund E, Aamdal S (2001)
Immunobead-based detection and characterization of circulating tumor cells in melanoma patients
Recent Results Cancer Res, 158, 40-50
DOI 10.1007/978-3-642-59537-0_5, PubMed 11092032

Aamdal S, Lund B, Koier I, Houten M, Wanders J, Verweij J (2000)
Phase I trial with weekly EO9, a novel bioreductive alkylating indoloquinone, by the EORTC Early Clinical Study Group (ECSG)
Cancer Chemother Pharmacol, 45 (1), 85-8
DOI 10.1007/PL00006748, PubMed 10647507

Pavlidis N, Aamdal S, Awada A, Calvert H, Fumoleau P, Sorio R, Punt C, Verweij J, van Oosterom A, Morant R, Wanders J, Hanauske AR (2000)
Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG)
Cancer Chemother Pharmacol, 46 (2), 167-71
DOI 10.1007/s002800000134, PubMed 10972487

Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, Gore M, Aamdal S, Cebon J, Coates A, Dreno B, Henz M, Schadendorf D, Kapp A, Weiss J, Fraass U, Statkevich P, Muller M, Thatcher N (2000)
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma
J Clin Oncol, 18 (1), 158-66
DOI 10.1200/JCO.2000.18.1.158, PubMed 10623706

Semb KA, Aamdal S, Bohmann T, Lucas C, Gerard B (1998)
Clinical experience of fotemustine, cisplatin and high dose tamoxifen in patients with metastatic malignant melanoma
Melanoma Res, 8 (6), 565-72
DOI 10.1097/00008390-199812000-00012, PubMed 9918419

Semb KA, Aamdal S, Oian P (1998)
Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment
J Clin Oncol, 16 (10), 3426-32
DOI 10.1200/JCO.1998.16.10.3426, PubMed 9779722

Semb KA, Aamdal S, Mette E, Ingvar C, Gullaksen N, Osmundsen K (1998)
Zilascorb(2H), a low-toxicity protein synthesis inhibitor that exhibits signs of anticancer activity in malignant melanoma
Anticancer Drugs, 9 (9), 797-802
DOI 10.1097/00001813-199810000-00009, PubMed 9840726

Jungnelius U, Ringborg U, Aamdal S, Mattsson J, Stierner U, Ingvar C, Malmström P, Andersson R, Karlsson M, Willman K, Wist E, Bjelkengren G, Westberg R (1998)
Dacarbazine-vindesine versus dacarbazine-vindesine-cisplatin in disseminated malignant melanoma. A randomised phase III trial
Eur J Cancer, 34 (9), 1368-74
DOI 10.1016/s0959-8049(98)00068-9, PubMed 9849419

Semb KA, Fodstad O, Klem B, Bibow K, Osmundsen K, Aamdal S (1997)
Zilascorb(2H), a new reversible protein synthesis inhibitor: clinical study of an oral preparation
Anticancer Drugs, 8 (3), 296-303
DOI 10.1097/00001813-199703000-00013, PubMed 9095337

Aamdal S, Bruntsch U, Kerger J, Verweij J, ten Bokkel Huinink W, Wanders J, Rastogi R, Franklin HR, Kaye SB (1997)
Zeniplatin in advanced malignant melanoma and renal cancer: phase II studies with unexpected nephrotoxicity
Cancer Chemother Pharmacol, 40 (5), 439-43
DOI 10.1007/s002800050683, PubMed 9272122

McLeod HL, Murray LS, Wanders J, Setanoians A, Graham MA, Pavlidis N, Heinrich B, ten Bokkel Huinink WW, Wagener DJ, Aamdal S, Verweij J (1996)
Multicentre phase II pharmacological evaluation of rhizoxin. Eortc early clinical studies (ECSG)/pharmacology and molecular mechanisms (PAMM) groups
Br J Cancer, 74 (12), 1944-8
DOI 10.1038/bjc.1996.657, PubMed 8980394

McLeod HL, Graham MA, Aamdal S, Setanoians A, Groot Y, Lund B (1996)
Phase I pharmacokinetics and limited sampling strategies for the bioreductive alkylating drug EO9. EORTC Early Clinical Trials Group
Eur J Cancer, 32A (9), 1518-22
DOI 10.1016/0959-8049(96)00120-7, PubMed 8911111

Semb KA, Aamdal S, Fosså SD, Oian P (1996)
Transcapillary forces of the subcutaneous tissue in patients treated with interleukin-2 and alpha-interferon: no capillary protein leak syndrome?
J Exp Ther Oncol, 1 (3), 155-61
PubMed 9414399

Hanauske AR, Catimel G, Aamdal S, ten Bokkel Huinink W, Paridaens R, Pavlidis N, Kaye SB, te Velde A, Wanders J, Verweij J (1996)
Phase II clinical trials with rhizoxin in breast cancer and melanoma. The EORTC Early Clinical Trials Group
Br J Cancer, 73 (3), 397-9
DOI 10.1038/bjc.1996.68, PubMed 8562349

Karlsson M, Jungnelius U, Aamdal S, Boeryd B, Carstensen J, Kågedal B, Westberg R, Wingren S (1996)
Correlation of DNA ploidy and S-phase fraction with chemotherapeutic response and survival in a randomized study of disseminated malignant melanoma
Int J Cancer, 65 (1), 1-5
DOI 10.1002/(SICI)1097-0215(19960103)65:1<1::AID-IJC1>3.0.CO;2-6, PubMed 8543385

Fosså SD, Aamdal S, Naume B, Gallati H (1995)
Serum levels of cytokines and soluble cytokine receptors in patients with metastatic renal cell carcinoma or malignant melanoma receiving IL-2/interferon-alpha combination therapy
Acta Oncol, 34 (5), 599-603
DOI 10.3109/02841869509094034, PubMed 7546824

Verweij J, Catimel G, Sulkes A, Sternberg C, Wolff I, Aamdal S, van Hoesel Q (1995)
Phase II studies of docetaxel in the treatment of various solid tumours. EORTC Early Clinical Trials Group and the EORTC Soft Tissue and Bone Sarcoma Group
Eur J Cancer, 31A Suppl 4, S21-4
DOI 10.1016/0959-8049(95)00362-m, PubMed 7577101

Aamdal S, Wolff I, Kaplan S, Paridaens R, Kerger J, Schachter J, Wanders J, Franklin HR, Verweij J (1994)
Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group
Eur J Cancer, 30A (8), 1061-4
DOI 10.1016/0959-8049(94)90456-1, PubMed 7654429

Verweij J, Aamdal S, Schellens J, Koier I, Lund B (1994)
Clinical studies with EO9, a new indoloquinone bioreductive alkylating cytotoxic agent. EORTC Early Clinical Trials Group
Oncol Res, 6 (10-11), 519-23
PubMed 7620220

Lundby B, Berg KJ, Lien HH, Aamdal S (1993)
A double blind study to evaluate the tolerability of gadodiamide injection and its effect on renal function in patients undergoing cerebral magnetic resonance imaging
Br J Radiol, 66 (790), 871-6
DOI 10.1259/0007-1285-66-790-871, PubMed 8220968

Gerard B, Aamdal S, Lee SM, Leyvraz S, Lucas C, D'Incalci M, Bizzari JP (1993)
Activity and unexpected lung toxicity of the sequential administration of two alkylating agents--dacarbazine and fotemustine--in patients with melanoma
Eur J Cancer, 29A (5), 711-9
DOI 10.1016/s0959-8049(05)80352-1, PubMed 8471329

Wibe E, Hannisdal E, Paus E, Aamdal S (1992)
Neuron-specific enolase as a prognostic factor in metastatic malignant melanoma
Eur J Cancer, 28A (10), 1692-5
DOI 10.1016/0959-8049(92)90070-i, PubMed 1389487

Aamdal S, Gerard B, Bohman T, D'Incalci M (1992)
Sequential administration of dacarbazine and fotemustine in patients with disseminated malignant melanoma--an effective combination with unexpected toxicity
Eur J Cancer, 28 (2-3), 447-50
DOI 10.1016/s0959-8049(05)80074-7, PubMed 1591062

Stoter G, Aamdal S, Rodenhuis S, Cleton FJ, Iacobelli S, Franks CR, Oskam R, Shiloni E (1991)
Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma: a multicenter phase II study
J Clin Oncol, 9 (9), 1687-91
DOI 10.1200/JCO.1991.9.9.1687, PubMed 1875225

Myklebust AT, Beiske K, Pharo A, Davies CD, Aamdal S, Fodstad O (1991)
Selection of anti-SCLC antibodies for diagnosis of bone marrow metastasis
Br J Cancer Suppl, 14, 49-53
PubMed 1645572

Wibe E, Paus E, Aamdal S (1990)
Neuron specific enolase (NSE) in serum of patients with malignant melanoma
Cancer Lett, 52 (1), 29-31
DOI 10.1016/0304-3835(90)90073-7, PubMed 2354416

Tefre T, Børresen AL, Aamdal S, Brøgger A (1990)
Studies of the L-myc DNA polymorphism and relation to metastasis in Norwegian lung cancer patients
Br J Cancer, 61 (6), 809-12
DOI 10.1038/bjc.1990.182, PubMed 1973618

Stoter G, Shiloni E, Aamdal S, Cleton FJ, Iacobelli S, Bijman JT, Palmer P, Franks CR, Rodenhuis S (1989)
Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma. A multicentre phase II study
Eur J Cancer Clin Oncol, 25 Suppl 3, S41-3
PubMed 2697578

Fodstad O, Kjønniksen I, Aamdal S, Nesland JM, Boyd MR, Pihl A (1988)
Extrapulmonary, tissue-specific metastasis formation in nude mice injected with FEMX-I human melanoma cells
Cancer Res, 48 (15), 4382-8
PubMed 3390834

Fodstad O, Aamdal S, McMenamin M, Nesland JM, Pihl A (1988)
A new experimental metastasis model in athymic nude mice, the human malignant melanoma LOX
Int J Cancer, 41 (3), 442-9
DOI 10.1002/ijc.2910410322, PubMed 3346110

Aamdal S, Fodstad O, Pihl A (1988)
Sodium thiosulfate fails to increase the therapeutic index of intravenously administered cis-diamminedichloroplatinum (II) in mice bearing murine and human tumors
Cancer Chemother Pharmacol, 21 (2), 129-33
DOI 10.1007/BF00257358, PubMed 3349560

Aamdal S, Fodstad O, Pihl A (1987)
Some procedures to reduce cis-platinum toxicity reduce antitumour activity
Cancer Treat Rev, 14 (3-4), 389-95
DOI 10.1016/0305-7372(87)90035-1, PubMed 3326670

Gundersen S, Aamdal S, Fodstad O (1987)
Mitozolomide (NSC 353451), a new active drug in the treatment of malignant melanoma. Phase II trial in patients with advanced disease
Br J Cancer, 55 (4), 433-5
DOI 10.1038/bjc.1987.85, PubMed 3580266

Aamdal S, Fodstad O, Kaalhus O, Pihl A (1986)
Chemosensitivity profiles of human cancers assessed by the 6-day SRC assay on serially xenografted tumors
Int J Cancer, 37 (4), 579-87
DOI 10.1002/ijc.2910370417, PubMed 3957463

Fodstad O, Aamdal S, Pihl A, Boyd MR (1985)
Activity of mitozolomide (NSC 353451), a new imidazotetrazine, against xenografts from human melanomas, sarcomas, and lung and colon carcinomas
Cancer Res, 45 (4), 1778-86
PubMed 3978640

Aamdal S, Fodstad O, Nesland JM, Pihl A (1985)
Characteristics of human tumour xenografts transplanted under the renal capsule of immunocompetent mice
Br J Cancer, 51 (3), 347-56
DOI 10.1038/bjc.1985.46, PubMed 3970811

Aamdal S, Fodstad O, Pihl A (1985)
The six-day subrenal capsule assay (SRCA) for testing the response of human tumours to anticancer agents. Validity and usefulness in cancer research and treatment
Ann Chir Gynaecol Suppl, 199, 51-9
PubMed 3864392

Aamdal S, Fodstad O, Pihl A (1985)
Methodological aspects of the 6-day subrenal capsule assay for measuring the response of human tumors to anticancer agents
Anticancer Res, 5 (4), 329-37
PubMed 4037730

Aamdal S, Fodstad O, Pihl A (1984)
Human tumor xenografts transplanted under the renal capsule of conventional mice. Growth rates and host immune response
Int J Cancer, 34 (5), 725-30
DOI 10.1002/ijc.2910340521, PubMed 6500747

Aamdal S, Fodstad O, Kaalhus O, Pihl A (1984)
Reduced antineoplastic activity in mice of cisplatin administered with high salt concentration in the vehicle
J Natl Cancer Inst, 73 (3), 743-52
PubMed 6590919

Aamdal S, Børmer O, Jørgensen O, Høst H, Eliassen G, Kaalhus O, Pihl A (1984)
Estrogen receptors and long-term prognosis in breast cancer
Cancer, 53 (11), 2525-9
DOI 10.1002/1097-0142(19840601)53:11<2525::aid-cncr2820531126>3.0.co;2-8, PubMed 6713348

Fodstad O, Kvalheim G, Godal A, Lotsberg J, Aamdal S, Høst H, Pihl A (1984)
Phase I study of the plant protein ricin
Cancer Res, 44 (2), 862-5
PubMed 6692385

Review articles

Geisler J, Bachmann IM, Nyakas M, Helsing P, Fjøsne HE, Mæhle LO, Aamdal S, Eide NA, Svendsen HL, Straume O, Robsahm TE, Jacobsen KD, Akslen LA (2013)
Malignant melanoma--diagnosis, treatment and follow-up in Norway
Tidsskr Nor Laegeforen, 133 (20), 2154-9
DOI 10.4045/tidsskr.12.1416, PubMed 24172628

Zwierzina H, Bergmann L, Fiebig H, Aamdal S, Schöffski P, Witthohn K, Lentzen H (2011)
The preclinical and clinical activity of aviscumine: a potential anticancer drug
Eur J Cancer, 47 (10), 1450-7
DOI 10.1016/j.ejca.2011.02.022, PubMed 21482461

Jacobsen KD, Fosså SD, Aamdal S (2006)
[Malignant melanoma--diagnosis and treatment]
Tidsskr Nor Laegeforen, 126 (23), 3094-7
PubMed 17160112

Hovig E, Myklebost O, Aamdal S, Smeland EB (2001)
[Gene therapy in cancer]
Tidsskr Nor Laegeforen, 121 (4), 482-8
PubMed 11255868

Other articles

Brunsvig PF, Guren TK, Nyakas M, Steinfeldt-Reisse CH, Rasch W, Kyte JA, Juul HV, Aamdal S, Gaudernack G, Inderberg EM (2020)
Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer
Front Immunol, 11, 572172
DOI 10.3389/fimmu.2020.572172, PubMed 33324397

Dueland S, Guren TK, Boberg KM, Reims HM, Grzyb K, Aamdal S, Julsrud L, Line PD (2017)
Acute liver graft rejection after ipilimumab therapy
Ann Oncol, 28 (10), 2619-2620
DOI 10.1093/annonc/mdx281, PubMed 28961840

Prasmickaite L, Skrbo N, Høifødt HK, Suo Z, Engebråten O, Gullestad HP, Aamdal S, Fodstad Ø, Maelandsmo GM (2010)
Human malignant melanoma harbours a large fraction of highly clonogenic cells that do not express markers associated with cancer stem cells
Pigment Cell Melanoma Res, 23 (3), 449-51
DOI 10.1111/j.1755-148X.2010.00690.x, PubMed 20236249

Warloe T, Aamdal S, Reith A, Bryne M (2006)
[Retraction of: Diagnostics and treatment of early stages of oral cancer]
Tidsskr Nor Laegeforen, 126 (17), 2287
PubMed 16967079

Sudbø J, Warloe T, Aamdal S, Reith A, Bryne M (2001)
[Diagnosis and treatment of oral precancerous lesions]
Tidsskr Nor Laegeforen, 121 (26), 3066-71 (Retracted)
PubMed 11757442

Sessa C, Aamdal S, Wolff I, Eppelbaum R, Smyth JF, Sulkes A, Ten Bokkel Huinink W, Vermorken J, Wanders J, Franklin H (1994)
Gemcitabine in patients with advanced malignant melanoma or gastric cancer: phase II studies of the EORTC Early Clinical Trials Group
Ann Oncol, 5 (5), 471-2
DOI 10.1093/oxfordjournals.annonc.a058884, PubMed 8075055

Aamdal S (1992)
Can ondansetron hydrochloride (Zofran) enhance the nephrotoxic potential of other drugs?
Ann Oncol, 3 (9), 774
DOI 10.1093/oxfordjournals.annonc.a058342, PubMed 1450070

Flørenes VA, Aamdal S, Myklebost O, Maelandsmo GM, Bruland OS, Fodstad O (1992)
Levels of nm23 messenger RNA in metastatic malignant melanomas: inverse correlation to disease progression
Cancer Res, 52 (21), 6088-91
PubMed 1356624

Beiske K, Myklebust AT, Aamdal S, Langholm R, Jakobsen E, Fodstad O (1992)
Detection of bone marrow metastases in small cell lung cancer patients. Comparison of immunologic and morphologic methods
Am J Pathol, 141 (3), 531-8
PubMed 1381558

Books

Andersen S, Aamdal S (1996)
Med viten og vilje: finn trivselsvekten - og behold den!
Vekt & helse, Østerås (2. utg.), 72 s.
BIBSYS 960552200

Andersen S, Aamdal S (1995)
Med viten og vilje: finn trivselsvekten - og behold den!
Vekt & helse, Østerås, 72 s.
BIBSYS 95262771x

Aamdal S (1986)
The 6-day subrenal capsule assay for testing the responseof human tumours to anticancer agents: by Steinar Aamdal
The Norwegian Cancer Society, Oslo, 1 b.(flere pag.)
BIBSYS 864072651, ISBN 82-90187-18-1